|1.||Verweij, Paul E: 5 articles (05/2015 - 01/2008)|
|2.||Marchetti, Oscar: 4 articles (12/2015 - 08/2005)|
|3.||Meis, Jacques F: 4 articles (05/2015 - 02/2012)|
|4.||Wiederhold, Nathan P: 4 articles (01/2012 - 06/2007)|
|5.||Gibson, P G: 4 articles (01/2004 - 01/2000)|
|6.||Sanglard, Dominique: 3 articles (12/2015 - 11/2002)|
|7.||Bassetti, Matteo: 3 articles (06/2015 - 01/2006)|
|8.||De Rosa, Francesco Giuseppe: 3 articles (06/2015 - 12/2013)|
|9.||Lass-Flörl, C: 3 articles (06/2015 - 01/2010)|
|10.||Mouton, Johan W: 3 articles (05/2015 - 07/2014)|
09/01/2010 - "Azoles are currently the most widely used class of antifungal drugs clinically, and are effective for treating fungal infections. "
11/01/2008 - "Formulation and drug delivery strategies can improve the aqueous wetting and dissolution properties by increasing their chemical potential, stabilizing the drug delivery system and targeting high concentration of the azoles to the infection sites, therefore enhancing the bioavailability and therapeutic efficacy of azole antifungals."
03/01/2015 - "As azoles are less effective against infections caused by multiply azole-resistant A. "
12/01/2003 - "Improved knowledge of its pathophysiology and the availability of new compounds for antifungal therapy and prophylaxis have contributed to improving the prognosis of severe candidal infections among immunosuppressed patients at the possible cost of the emergence of non-albicans strains of candida with lower susceptibility to azoles. "
07/10/1999 - "Placebo controlled trials yielded pooled relative risks of failure to cure skin infections: allylamines (0.30, 95% confidence interval 0.24 to 0.38); azoles (0.54, 0.42 to 0.68); undecenoic acid (0.28, 0. "
01/01/2010 - "The systemic azoles, are generally safe and effective agents in HIV-infected patients with oropharyngeal candidiasis. "
11/01/2015 - "These results suggest that combinations of K20 and azoles offer a possible strategy for developing therapies against candidiasis. "
12/01/2014 - "Combination therapy would be one of the best strategies for the treatment of candidiasis due to increased resistance to azoles. "
08/01/2013 - "Oropharyngeal candidiasis (OPC) occurs in about 90% of HIV-infected individuals, and 4 to 5% are refractory to current therapies, including azoles, due to the formation of resistant biofilms produced in the course of OPC. "
01/01/2012 - "Taken together, our work provides a potential application to combat candidiasis using the combination of RAB and azoles."
10/01/2012 - "Are epidemiologic cut-off values predictors of the in vivo efficacy of azoles in experimental aspergillosis?"
06/01/2015 - "fumigatus was more frequently found (3.2% prevalence) than previously acknowledged, causing resistant invasive and noninvasive aspergillosis and severely compromising clinical use of azoles. "
05/01/2015 - "Alternative treatments with new azoles may improve therapeutic outcome in invasive aspergillosis (IA) even for strains with decreased susceptibility to current azoles. "
01/01/2015 - "Although cross-resistance within the azoles seems to be common, the role of azoles in the management of azole-resistant aspergillosis remains unclear, but optimizing drug exposure is critical for treatment success. "
07/01/2014 - "The role of azoles in the management of azole-resistant aspergillosis: from the bench to the bedside."
02/01/2014 - "As to the choice of antifungals, we should also take into account the ability of antibiofilm effect of antifungals as well as immunological state of host including neutropenia, prior administration of azoles, isolated or estimated Candida species, sensitivity against antifungals, administration route, pharmacokinetics (bioavailability, metabolic and excretion pathway, distribution) and drug interaction. "
03/01/2013 - "Survival was poorer for patients with prior broad spectrum azoles (p<0.05), and for those who did not recover from neutropenia (p<0.05). "
08/01/2004 - "Haematological malignancies and neutropenia were associated with less frequent initial prescription of azoles [OR = 0.3 (0.1-0.8) and OR = 0.3 (0.1-0.9), respectively]. "
03/01/2013 - "The group with prior mold-active azoles included more patients with poor risk features for IFI as acute myeloid leukemia (p<0.05) and prolonged neutropenia (p<0.05). "
08/01/2004 - "In aspergillosis, younger age and neutropenia were associated with less frequent initial prescription of azoles [OR = 0.03 (0.002-0.6) and OR = 0.09 (0.03-0.3), respectively] and previous history of IFI was associated with a higher probability of azole prescription [OR = 17.2 (2.4-124.3)]. "
09/01/2010 - "Potassium iodide is an effective treatment for sporotrichosis, but this agent has not been subjected to specific treatment trials comparing its efficacy against azoles or allylamine alternatives. "
04/01/1989 - "From the first report of the efficacy of the iodides for the treatment of sporotrichosis (1903) until the introduction of the imidazoles (azoles, 1960s), the number of antifungal agents available was very limited, including griseofulvin (1939), nystatin (1950), amphotericin B (1956), and flucytosine (1964). "
|1.||Amphotericin B (Amphotericin)
|1.||Transplantation (Transplant Recipients)
|2.||Drug Therapy (Chemotherapy)